On Tuesday, Vertex Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. Keep an eye out to see if VRTX stock sees more buying action from institutional investors.
The new Composite score means the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.
VRTX stock is now out of buy range after clearing the 247.59 entry in a cup with handle. The market is also in a correction. It's best to wait for a confirmed uptrend before purchasing new stocks.
See How IBD Helps You Make More Money In Stocks
VRTX Stock Boast Strong Earnings Numbers
The stock earns a 97 EPS Rating, meaning its recent quarterly and longer-term annual earnings growth is outpacing 97% of all stocks.
Vertex's Accumulation/Distribution Rating of C shows a roughly equal amount of buying and selling by institutional investors over the last 13 weeks.
Vertex Pharmaceuticals posted an 18% EPS gain for Q1. Top line growth fell to 22%, down from 27% in the prior quarter.
VRTX stock holds the No. 2 rank among its peers in the Medical-Biomed/Biotech industry group. Pacira Pharmaceuticals is the No. 1-ranked stock within the group.
